Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
20.52B | 20.66B | 20.55B | 19.17B | 19.48B | 17.64B | Gross Profit |
9.71B | 11.86B | 16.96B | 15.90B | 16.16B | 14.66B | EBIT |
3.52B | 5.96B | 2.51B | 2.33B | 2.87B | 1.99B | EBITDA |
4.44B | 6.89B | 3.39B | 3.33B | 3.42B | 2.43B | Net Income Common Stockholders |
1.46B | 3.20B | 611.00M | 1.00B | 1.48B | 768.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
3.00B | 3.02B | 1.23B | 858.00M | 2.36B | 2.45B | Total Assets |
29.24B | 28.94B | 28.31B | 27.16B | 27.58B | 27.11B | Total Debt |
13.17B | 13.17B | 16.21B | 15.08B | 15.65B | 15.72B | Net Debt |
10.17B | 10.15B | 14.98B | 14.22B | 13.28B | 13.27B | Total Liabilities |
20.58B | 20.39B | 22.80B | 22.55B | 23.32B | 24.22B | Stockholders Equity |
4.18B | 4.17B | 1.61B | 1.14B | 1.03B | 28.00M |
Cash Flow | Free Cash Flow | ||||
1.42B | 1.12B | 1.62B | 321.00M | 910.00M | 2.87B | Operating Cash Flow |
2.28B | 2.05B | 2.37B | 1.08B | 1.57B | 3.41B | Investing Cash Flow |
-117.00M | 3.43B | -969.00M | -808.00M | -714.00M | -1.61B | Financing Cash Flow |
-1.64B | -3.69B | -1.03B | -1.78B | -936.00M | 385.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $16.69B | 25.02 | 4.36% | 2.77% | ― | ― | |
76 Outperform | $88.67B | 16.38 | -230.22% | 0.78% | 7.30% | 11.60% | |
71 Outperform | $15.26B | 10.86 | 38.12% | ― | -1.79% | -41.85% | |
68 Neutral | $12.15B | 24.88 | 25.33% | 0.56% | 11.21% | 30.38% | |
64 Neutral | $10.98B | 9.57 | 18.35% | 0.47% | 9.73% | 51.87% | |
64 Neutral | $10.41B | 13.51 | 260.92% | ― | 5.11% | 14.28% | |
54 Neutral | $5.34B | 3.36 | -45.10% | 3.39% | 16.81% | -0.03% |
On May 30, 2025, Tenet Healthcare Corporation announced the promotion of Lisa Y. Foo to the newly created position of Chief Operating Officer, effective immediately. This strategic move is expected to enhance the company’s operational leadership and potentially strengthen its market position.
The most recent analyst rating on (THC) stock is a Buy with a $136.00 price target. To see the full list of analyst forecasts on Tenet Healthcare stock, see the THC Stock Forecast page.
On May 22, 2025, Tenet Healthcare Corporation held its Annual Meeting of Shareholders, where several key decisions were made. Shareholders elected directors to the board, approved executive compensation, and ratified Deloitte & Touche LLP as the independent accountants for 2025. However, a proposal for a report on improving maternal health outcomes was not approved, indicating a lack of consensus on this issue among shareholders.
The most recent analyst rating on (THC) stock is a Buy with a $184.00 price target. To see the full list of analyst forecasts on Tenet Healthcare stock, see the THC Stock Forecast page.